Therefore, it is likely that administration of anti‐CD47 and/or anti‐SIRPα mAb interferes Akt and NF‐κB activation in macrophages, influencing macrophages migration, survival, cytokines production, and/or angiogenesis in tumor sites.44 We have demonstrated that anti‐SIRPα mAb promotes phagocytic activity of macrophages not only against hepatoma but also against colon carcinoma cells, but anti‐CD47 mAb does not. The gene discussed is SIRPA; the disease is hepatocellular carcinoma.